Luis Castelo-Branco: Belzutifan vs everolimus for advanced kidney cancer

Luis Castelo-Branco shared a post on X:

”Belzutifan vs everolimus for advanced kidney cancer: NO survival benefit. NO toxicity/safety benefit. Ethically, at the moment, this is the main data that we should discuss for clinical and regulatory decisions.”

Bishal Gyawali shared a post by Luis Castelo-Branco, on X, adding:

”Agree completely. I talk about this trail in my ESMO24 round up video.”

View attached video.
Source: Luis Castelo-Branco/X and Bishal Gyawali/X

Luis Castelo-Branco is a Medical Oncologist and a researcher. He works at Ente Ospedaliero Cantonale (EOC), where he serves as a consultant for cancer care and strategic planning. He is also a consultant for the World Health Organization (WHO). Dr. Castelo-Branco’s post-doctoral research focuses on cancer public health, policy, and collaborative research in real-world evidence.

Bishal Gyawali, MD, PhD, is a medical oncologist from Nepal. Currently an Associate Professor at Queen’s University, Kingston, Canada, and affiliated with Brigham and Women’s Hospital, Boston, USA, he is involved in global oncology initiatives. Dr. Gyawali serves on several committees, including the WHO Essential Medicines List Cancer Medicines Working Group and ASCO’s Health Equity and Outcomes Committee, contributing significantly to cancer policy and evidence-based oncology.